Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever.

We report a Japanese patient with familial Mediterranean fever (FMF) who was successfully treated with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab, and low-dose methotrexate. This patient was diagnosed as having FMF based on periodic fever with polyarthralgia typical of this disease and heterozygous mutations in the MEFV gene. Conventional treatment, such as colchicine and reserpine, failed to sufficiently control the FMF attacks. After starting infliximab (3 mg/kg) and low-dose methotrexate (6 mg/week), the frequency of the FMF attacks dramatically decreased and the clinical effect has remained unchanged for longer than 1 year. Combination therapy with infliximab and low-dose methotrexate may be a potent therapeutic option for FMF patients, particularly when conventional treatment is ineffective or cannot be employed because of adverse events.

[1]  M. Pillinger,et al.  Familial Mediterranean fever successfully treated with etanercept. , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[2]  H. Yazıcı,et al.  Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. , 2006, Clinical and experimental rheumatology.

[3]  S. Ozgoçmen,et al.  Familial Mediterranean fever responds well to infliximab: single case experience , 2006, Clinical Rheumatology.

[4]  A. Nakamura,et al.  A Japanese patient with familial Mediterranean fever associated with compound heterozygosity for pyrin variant E148Q/M694I. , 2005, Internal medicine.

[5]  T. Takeuchi,et al.  Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases , 2005 .

[6]  N. Uemura,et al.  Familial mediterranean fever medicated with an herbal medicine in Japan , 2004, Pediatrics international : official journal of the Japan Pediatric Society.

[7]  J. Yagüe,et al.  A severe autosomal‐dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: An unusual familial Mediterranean fever phenotype or another MEFV‐associated periodic inflammatory disorder? , 2004, American journal of medical genetics. Part A.

[8]  S. Akıncı,et al.  Serum sIL-2r, IL-6, IL-10 and TNF-α level in familial Mediterranean fever patients , 2003, Clinical Rheumatology.

[9]  D. Kastner,et al.  Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. , 2003, Molecular cell.

[10]  T. Roscioli,et al.  Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. , 2002, Blood.

[11]  H. Yazici,et al.  Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. , 2002, Clinical and experimental rheumatology.

[12]  A. Komiyama,et al.  Familial Mediterranean fever in 2 Japanese families. , 2002, The Journal of rheumatology.

[13]  J. Drenth,et al.  Hereditary periodic fever. , 2001, The New England journal of medicine.

[14]  H. Hanai,et al.  Treating Familial Mediterranean Fever with Prazosin Hydrochloride , 1998, Annals of Internal Medicine.

[15]  Y. Ouchi,et al.  Increased Synovial Interleukin-8 and Interleukin-6 Levels in Pseudogout Associated with Granulocyte Colony-Stimulating Factor , 1998, Annals of Internal Medicine.

[16]  E. Ben-Chetrit,et al.  Familial Mediterranean fever , 1998, The Lancet.

[17]  S. Akar,et al.  The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. , 1997, British journal of rheumatology.

[18]  A. Hayashi,et al.  PERIODIC FEVER SUPPRESSED BY RESERPINE , 1976, The Lancet.

[19]  L. Rosenman.  Letter: Surgery for gastric ulcer. , 1976, Lancet.

[20]  E. Sohar,et al.  FAMILIAL MEDITERRANEAN FEVER , 1959, Definitions.